rss Posted February 5, 2013 Report Share Posted February 5, 2013 Related ArticlesA New Treatment Regimen for Rosacea: OnabotulinumtoxinA. J Drugs Dermatol. 2012 Dec 1;11(12):e76-9 Authors: Dayan SH, Pritzker RN, Arkins JP Abstract Rosacea is a cutaneous condition with several clinical subtypes that are commonly seen in daily medical practice. There are many different treatment modalities for each of the physical !ndings associated with this disease, and all have varying results. As the use of onabotulinumtoxinA rises, its bene!t in the treatment of a growing number of medical diseases increases. The authors report anecdotal evidence of patients with rosacea experiencing improved symptoms of erythema and "ushing after treatment with intradermal, microdroplets of onabotulinumtoxinA. There were no adverse events reported for any of the treatments. The mechanism of action through a likely neurogenic component to vascular dysfunction, in"ammation, and hypersebaceous activity is reviewed. J Drugs Dermatol. 2012;11(12):e76-e79.PMID: 23377526 [PubMed - in process] http://www.ncbi.nlm.nih.gov/PubMed/23377526?dopt=Abstract = URL to article Link to comment Share on other sites More sharing options...
Guests Guest Posted February 5, 2013 Guests Report Share Posted February 5, 2013 OnabotulinumtoxinA (Tradename Botox), according to Wikipedia, "is the most acutely toxic substance known." Allergan makes Botox and Accutane. Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now